Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

First steps towards a vaccine for pancreatic cancer

22.09.2003


Research carried out in the United States has raised the hope that one day there could be a vaccine against pancreatic cancer – one of the most difficult cancers to treat successfully.



Dr Robert Maki told ECCO12 – The European Cancer Conference - today (Monday 22 September) that preliminary work with a cancer vaccine created from a heat-shock protein1 taken from the patient’s own tumour had resulted in one patient out of the ten vaccinated still alive and without disease after five years, and two more alive and without disease after more than two years. The typical survival after surgery for pancreas cancer is 14-15 months.

However, Dr Maki warned that patients should not get excited about the results of this research as it was too early to tell whether it would be possible to create a vaccine that could be used on all pancreatic cancer patients, and the patients involved in the trial had been carefully selected and might have been ones that would have done well anyway.


Dr Maki, an assistant member in the division of GI oncology in the department of medicine, and co-director of the sarcoma programme at the Memorial Sloan-Kettering Cancer Center in New York, USA, told delegates that he and his colleagues had run a phase I trial on 10 pancreatic patients using a vaccine based on a heat-shock protein called HSPPC-96 taken from the tumour of each patient (i.e. autologous).

Initial problems in creating the vaccine meant that the study was delayed half way through the study to improve the vaccine-making process. Dr Maki said: “The problem is that the pancreas makes digestive enzymes that destroy proteins . . . in other words, the pancreatic tumour cells themselves can destroy the vaccine you are trying to make, if you do not handle the tumour tissue carefully and quickly. With improvement in the vaccine purification process, most patients with the primary pancreatic cancer enrolled on the study were able to receive vaccinations.”

First, surgeons operated to remove completely the primary tumour, and then the patients were vaccinated within eight weeks of surgery. As far as doctors could tell, the patients were disease-free at the time of their vaccinations. None of the patients suffered side effects that limited the dose of the vaccine, and none had chemotherapy or radiotherapy.

Dr Maki said: “Tests on the patients showed that at least some people we examined made a response against the vaccine and therefore, hopefully, against the cancer. However, we will only get a better picture of the efficacy of this vaccine when we have the clinical results from a larger study.” The overall survival for the 10 patients was two and a half years, in comparison to 14.3 months, the historical average.

“Over 95% of people with pancreatic cancer die, typically within two years of diagnosis, and mortality is still about 90% even for those who have complete removal of their pancreatic cancer. So the finding of even a few patients surviving two years or more is promising regarding the usefulness of this vaccine after removal of the cancer. However, and this is a big however, we may be biased in who we selected for the study. Only people who could have an operation were eligible; we screened out people who had evidence of spread of tumor before they entered the study. Perhaps, just by chance, we got a few people who were destined to do well. So enthusiasm about any phase II study has to be tempered by the fact that you need a proper randomized study to determine the vaccine’s usefulness,” he said.

HSPPC-96 has been shown to have quite a dramatic effect in some patients with metastatic melanoma and so Dr Maki hopes that trials could be run to further test its efficacy against pancreatic cancer as well. In the meantime, until a larger study has been run, it will not be known for certain whether this vaccine has real potential against pancreatic cancer. Trials are also underway to test the vaccine in the treatment of kidney cancer.

The story of this vaccine is a good example of how earlier discoveries at the lab bench can eventually translate into potential new therapies for patients. Dr Maki’s PhD was based on cloning and purifying the human HSPCC-96 molecule. “It is nice to see that well over 10 years after my PhD, this interesting molecule is undergoing examination in the clinic. It is gratifying to see the studies move from the bench to patients, where I hope some benefit will be seen. Similarly, this same technique could be used in preparing vaccines against infectious diseases – another very large area of potential use for these vaccines.”

Mary Rice | alfa
Further information:
http://www.fecs.be/conferences/ecco12/media_updates.shtml

More articles from Health and Medicine:

nachricht One gene closer to regenerative therapy for muscular disorders
01.06.2017 | Cincinnati Children's Hospital Medical Center

nachricht The gut microbiota plays a key role in treatment with classic diabetes medication
01.06.2017 | University of Gothenburg

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Can we see monkeys from space? Emerging technologies to map biodiversity

An international team of scientists has proposed a new multi-disciplinary approach in which an array of new technologies will allow us to map biodiversity and the risks that wildlife is facing at the scale of whole landscapes. The findings are published in Nature Ecology and Evolution. This international research is led by the Kunming Institute of Zoology from China, University of East Anglia, University of Leicester and the Leibniz Institute for Zoo and Wildlife Research.

Using a combination of satellite and ground data, the team proposes that it is now possible to map biodiversity with an accuracy that has not been previously...

Im Focus: Climate satellite: Tracking methane with robust laser technology

Heatwaves in the Arctic, longer periods of vegetation in Europe, severe floods in West Africa – starting in 2021, scientists want to explore the emissions of the greenhouse gas methane with the German-French satellite MERLIN. This is made possible by a new robust laser system of the Fraunhofer Institute for Laser Technology ILT in Aachen, which achieves unprecedented measurement accuracy.

Methane is primarily the result of the decomposition of organic matter. The gas has a 25 times greater warming potential than carbon dioxide, but is not as...

Im Focus: How protons move through a fuel cell

Hydrogen is regarded as the energy source of the future: It is produced with solar power and can be used to generate heat and electricity in fuel cells. Empa researchers have now succeeded in decoding the movement of hydrogen ions in crystals – a key step towards more efficient energy conversion in the hydrogen industry of tomorrow.

As charge carriers, electrons and ions play the leading role in electrochemical energy storage devices and converters such as batteries and fuel cells. Proton...

Im Focus: A unique data centre for cosmological simulations

Scientists from the Excellence Cluster Universe at the Ludwig-Maximilians-Universität Munich have establised "Cosmowebportal", a unique data centre for cosmological simulations located at the Leibniz Supercomputing Centre (LRZ) of the Bavarian Academy of Sciences. The complete results of a series of large hydrodynamical cosmological simulations are available, with data volumes typically exceeding several hundred terabytes. Scientists worldwide can interactively explore these complex simulations via a web interface and directly access the results.

With current telescopes, scientists can observe our Universe’s galaxies and galaxy clusters and their distribution along an invisible cosmic web. From the...

Im Focus: Scientists develop molecular thermometer for contactless measurement using infrared light

Temperature measurements possible even on the smallest scale / Molecular ruby for use in material sciences, biology, and medicine

Chemists at Johannes Gutenberg University Mainz (JGU) in cooperation with researchers of the German Federal Institute for Materials Research and Testing (BAM)...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Plants are networkers

19.06.2017 | Event News

Digital Survival Training for Executives

13.06.2017 | Event News

Global Learning Council Summit 2017

13.06.2017 | Event News

 
Latest News

Quantum thermometer or optical refrigerator?

23.06.2017 | Physics and Astronomy

A 100-year-old physics problem has been solved at EPFL

23.06.2017 | Physics and Astronomy

Equipping form with function

23.06.2017 | Information Technology

VideoLinks
B2B-VideoLinks
More VideoLinks >>>